RT Journal Article
T1 Preventive Strategies Against Cytomegalovirus and Incidence of α-Herpesvirus Infections in Solid Organ Transplant Recipients: A Nationwide Cohort Study.
A1 Martin-Gandul, C
A1 Stampf, S
A1 Héquet, D
A1 Mueller, N J
A1 Cusini, A
A1 van Delden, C
A1 Khanna, N
A1 Boggian, K
A1 Hirzel, C
A1 Soccal, P
A1 Hirsch, H H
A1 Pascual, M
A1 Meylan, P
A1 Manuel, O
A1 Swiss Transplant Cohort Study (STCS), 
K1 antibiotic: antiviral-ganciclovir/valganciclovir
K1 clinical research/practice
K1 infection and infectious agents
K1 infectious disease
K1 viral
K1 viral: herpes zoster/Varicella
AB We assessed the impact of antiviral preventive strategies on the incidence of herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections in a nationwide cohort of transplant recipients. Risk factors for the development of HSV or VZV infection were assessed by Cox proportional hazards regression. We included 2781 patients (56% kidney, 20% liver, 10% lung, 7.3% heart, 6.7% others). Overall, 1264 (45%) patients received antiviral prophylaxis (ganciclovir or valganciclovir, n = 1145; acyclovir or valacyclovir, n = 138). Incidence of HSV and VZV infections was 28.9 and 12.1 cases, respectively, per 1000 person-years. Incidence of HSV and VZV infections at 1 year after transplant was 4.6% (95% confidence interval [CI] 3.5-5.8) in patients receiving antiviral prophylaxis versus 12.3% (95% CI 10.7-14) in patients without prophylaxis; this was observed particularly for HSV infections (3% [95% CI 2.2-4] versus 9.8% [95% CI 8.4-11.4], respectively). A lower rate of HSV and VZV infections was also seen in donor or recipient cytomegalovirus-positive patients receiving ganciclovir or valganciclovir prophylaxis compared with a preemptive approach. Female sex (hazard ratio [HR] 1.663, p = 0.001), HSV seropositivity (HR 5.198, p
YR 2017
FD 2017-02-02
LK http://hdl.handle.net/10668/10728
UL http://hdl.handle.net/10668/10728
LA en
DS RISalud
RD Apr 5, 2025